Larimar Therapeutics (LRMR) Payables: 2013-2020
Historic Payables for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $1.3 million.
- Larimar Therapeutics' Payables fell 88.02% to $1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $21.9 million, marking a year-over-year decrease of 44.32%. This contributed to the annual value of $10.8 million for FY2019, which is 19.54% up from last year.
- As of Q3 2020, Larimar Therapeutics' Payables stood at $1.3 million, which was down 43.80% from $2.3 million recorded in Q2 2020.
- Over the past 5 years, Larimar Therapeutics' Payables peaked at $24.0 million during Q1 2018, and registered a low of $1.3 million during Q3 2020.
- Its 3-year average for Payables is $12.0 million, with a median of $10.4 million in 2019.
- As far as peak fluctuations go, Larimar Therapeutics' Payables skyrocketed by 486.38% in 2018, and later tumbled by 88.02% in 2020.
- Larimar Therapeutics' Payables (Quarterly) stood at $6.2 million in 2016, then skyrocketed by 273.64% to $23.0 million in 2017, then slumped by 60.71% to $9.0 million in 2018, then increased by 19.54% to $10.8 million in 2019, then tumbled by 88.02% to $1.3 million in 2020.
- Its Payables was $1.3 million in Q3 2020, compared to $2.3 million in Q2 2020 and $7.6 million in Q1 2020.